echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Fosun Pharma Holding Subsidiary's Trastuzumab for Injection Obtained Notice of Approval of Supplementary Drug Application

    Fosun Pharma Holding Subsidiary's Trastuzumab for Injection Obtained Notice of Approval of Supplementary Drug Application

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 17, Fosun Pharma issued an announcement stating that its controlling subsidiary Hanlius Pharmaceuticals had received the "Drug Supplementary Application for Trastuzumab for Injection (trade name: Hanquyou®) issued by the National Medical Products Administration.


    The drug is a monoclonal antibody biosimilar independently developed by the Group (ie the company and its holding subsidiaries/units, the same below).


    As of the date of this announcement, the trastuzumab approved for marketing in China includes Roche's Herceptin® and Hanlin Pharmaceutical's Hantrauyou®


    As of July 2021, the Group’s current cumulative R&D investment for the drug is approximately RMB 979.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.